سعر ليفوكار 50/200مجم سي ار 10 اقراص 2022

Controlled-release tablet containing carbidopa 50 mg + levodopa 200 mg, pack of 10 controlled-release tablets, by Alfacure pharmaceuticals (Egypt); antiparkinsonian combination of levodopa with the decarboxylase inhibitor carbidopa.

• Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide or manganese intoxication.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions are dyskinesias (choreiform, dystonic and other involuntary movements) and nausea; others include orthostatic hypotension, confusion, hallucinations, dizziness, somnolence, depression, dark saliva, urine or sweat, and rare blood dyscrasias.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Nonselective monoamine oxidase (MAO) inhibitors are contraindicated; they must be stopped at least two weeks before starting therapy (selective MAO-B inhibitors such as selegiline may be used at the recommended dose).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Contraindicated in known hypersensitivity to any component and in narrow-angle glaucoma.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Levodopa given without a decarboxylase inhibitor must be stopped at least 12 hours before starting; CNS effects such as dyskinesias may occur at lower doses and sooner than with levodopa alone.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Observe all patients for depression with suicidal tendencies; use cautiously in severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease, after myocardial infarction with residual arrhythmias, and with a history of peptic ulcer (risk of upper GI haemorrhage).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Treatment may contribute to vitamin B6 deficiency; seizures associated with vitamin B6 deficiency, refractory to anti-seizure medicines and resolving only after vitamin B6, have been reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Antihypertensive drugsSymptomatic postural hypotension may occur; the antihypertensive dose may need adjustment.DailyMed (U.S. National Library of Medicine)
• Tricyclic antidepressantsRare reports of hypertension and dyskinesia.DailyMed (U.S. National Library of Medicine)
• Dopamine D2 antagonists (phenothiazines, butyrophenones, risperidone), isoniazid, phenytoin, papaverineMay reduce or reverse the therapeutic effect of levodopa; observe for loss of response.DailyMed (U.S. National Library of Medicine)

• No adequate, well-controlled studies in pregnant women; visceral and skeletal malformations occurred in rabbits; use in women of childbearing potential requires weighing benefits against possible hazards to mother and child.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Levodopa has been detected in human milk; use caution in nursing women.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Carbidopa: Carbidopa inhibits decarboxylation of peripheral levodopa; it does not cross the blood-brain barrier and does not affect levodopa metabolism within the central nervous system (US label).
• Levodopa: Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is presumably converted to dopamine in the brain, which is thought to relieve the symptoms of Parkinson's disease (US label).